tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Repligen’s Strong Q2 Performance and Growth Prospects Justify Buy Rating
PremiumRatingsRepligen’s Strong Q2 Performance and Growth Prospects Justify Buy Rating
13d ago
Repligen reports Q2 adjusted EPS 37c, consensus 39c
Premium
The Fly
Repligen reports Q2 adjusted EPS 37c, consensus 39c
13d ago
Repligen sees FY25 non-GAAP EPS $1.65-$1.72, consensus $1.68
Premium
The Fly
Repligen sees FY25 non-GAAP EPS $1.65-$1.72, consensus $1.68
13d ago
Regeneron Stock (REGN) Retreats as Lung Disease Drug Data Disappoints
PremiumMarket NewsRegeneron Stock (REGN) Retreats as Lung Disease Drug Data Disappoints
2M ago
Repligen Holds Annual Shareholders Meeting, Key Decisions Made
Premium
Company Announcements
Repligen Holds Annual Shareholders Meeting, Key Decisions Made
3M ago
Repligen’s Strategic Growth and Resilience Drive Buy Rating with $180 Price Target
Premium
Ratings
Repligen’s Strategic Growth and Resilience Drive Buy Rating with $180 Price Target
3M ago
Repligen’s Earnings Call Highlights Robust Growth and Strategic Moves
PremiumCompany AnnouncementsRepligen’s Earnings Call Highlights Robust Growth and Strategic Moves
3M ago
Repligen price target lowered to $190 from $200 at JPMorgan
Premium
The Fly
Repligen price target lowered to $190 from $200 at JPMorgan
3M ago
Repligen upgraded to Outperform from Peer Perform at Wolfe Research
Premium
The Fly
Repligen upgraded to Outperform from Peer Perform at Wolfe Research
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100